Absolute bioavailability and effect of formulation change, food, or elevated pH with rabeprazole on cobimetinib absorption in healthy subjects

Molecular Pharmaceutics

Volumn 10, Issue 11, 2013, Pages 4046-4054

  Musib, Luna ^a   Choo, Edna ^a   Deng, Yuzhong ^a   Eppler, Steve ^a   Rooney, Isabelle ^a   Chan, Iris T ^a   Dresser, Mark J ^a  

^a GENENTECH INC   (United States)

Author keywords

absolute bioavailability; cobimetinib; food effect; oral absorption; proton pump inhibitor

Indexed keywords

COBIMETINIB; RABEPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG CLEARANCE; DRUG EXPOSURE; DRUG FORMULATION; DRUG METABOLISM; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOOD; HEADACHE; HUMAN; LIPID DIET; LYMPHADENITIS; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PARTICLE SIZE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; STOMACH PH; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; AZETIDINES; BIOLOGICAL AVAILABILITY; FEMALE; FOOD; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; PIPERIDINES; PROTON PUMP INHIBITORS; RABEPRAZOLE; YOUNG ADULT;

EID: 84887374003     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400383x     Document Type: Article

References (20)

1. Roberts, P. J.; Der, C. J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 2007, 26, 3291-3310
2. Johnson, G. L.; Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases Science 2002, 298, 1911-1912
3. Choo, E. F.; Belvin, M.; Boggs, J.; Deng, Y.; Hoeflich, K. P.; Ly, J.; Merchant, M.; Orr, C.; Plise, E.; Robarge, K.; Martini, J. F.; Kassees, R.; Aoyama, R. G.; Ramaiva, A.; Johnston, S. H. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions Drug Metab. Dispos. 2012, 40, 919-927
4. Musib, L.; Eppler, S.; Choo, E.; Deng, A.; Miles, D.; Hsu, B.; Rosen, L.; Sikic, B.; LoRusso, P.; Ma, W.; Goldman, J.; Fisher, G.; Weise, A.; Dy, G.; Chan, I.; Ware, J. Clinical pharmacokinetics of GDC-0973, an oral MEK inhibitor, in cancer patients: data from a Phase 1 study. Presented at American Association for Cancer Research, 102nd Annual Meeting; April 2-6, 2011; Orlando, FL.
5. Smelick, G. S.; West, D. A.; Chu, L. K.; DuVall, S. L.; Holden, S. N.; Frymoyer, A. R.; Benet, L. Z.; Dresser, M. J.; Ware, J. A. Prevalence of acid-reducing agents in cancer populations: an epidemiological perspective to predict drug-drug interaction potential of orally administered pH-dependent cancer therapeutics. Presented at American Society for Clinical Pharmacology and Therapeutics, 113th Annual Meeting; March 12-17, 2012; National Harbor, MD.
6. Budha, N. R.; Frymoyer, A.; Smelick, G. S.; Jin, J. Y.; Yago, M. R.; Dresser, M. J.; Holden, S. N.; Benet, L. Z.; Ware, J. A. Drug absorption interactions between oral targeted anticancer agents and PPIs: Is pH-dependent solubility the Achilles heel of targeted therapy? Clin. Pharmacol. Ther. 2012, 92, 203-213
7. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry: Food Effect Bioavailability and Fed Bioequivalence Studies; US Food and Drug Administration: Rockville, MD, 2002.
8. Rosen, L.; LoRusso, P.; Ma, W. W.; Goldman, J.; Weise, A.; Colevas, A.; Adjei, A.; Yazji, S.; Shen, A.; Johnston, S.; Gates, M.; Jones, C.; Musib, L.; de Crespigny, A.; Chan, I.; Sikic, B. I. A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors. Presented at American Association for Cancer Research, 102nd Annual Meeting; April 2-6, 2011; Orlando, FL.
9. Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans Pharm. Res. 1993, 10, 1093-1095
10. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System; US Food and Drug Administration: Rockville, MD, 2000.
11. Custodio, J. M.; Wu, C. Y.; Benet, L. Z. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption Adv. Drug Delivery Rev. 2008, 60, 717-733
12. Fleisher, D.; Li, C.; Zhou, Y.; Pao, L. H.; Karim, A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications Clin. Pharmacokinet. 1999, 36, 233-254
13. Singh, B. N. Effects of food on clinical pharmacokinetics Clin. Pharmacokinet. 1999, 37, 213-255
14. European Medicines Agency (EMEA). Guideline on the Investigation of Drug Interactions; CPMP/EWP/560/95/Rev 1; Committee for Human Medicinal Products (CHMP): London, 2010.
15. Carver, P. L.; Fleisher, D.; Zhou, S. Y.; Kaul, D.; Kazanjian, P.; Li, C. Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients Pharm. Res. 1999, 16, 718-724
16. Tschanz, C.; Stargel, W. W.; Thomas, J. A. Interactions between drugs and nutrients Adv. Pharmacol. 1996, 35, 1-26
17. Williams, M. P.; Sercombe, J.; Hamilton, M. I.; Pounder, R. E. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects Aliment. Pharmacol. Ther. 1998, 12, 1079-1789
18. Swan, S. K.; Hoyumpa, A. M.; Merritt, G. J. Review article: the pharmacokinetics of rabeprazole in health and disease Aliment. Pharmacol. Ther. 1999, 13 (Suppl. 3) 1-17
19. Rowland, M.; Tozer, T. Clinical Pharmacokinetics: Concepts and Applications, 3 rd ed.; Williams and Wilkins: Philadelphia, PA, 1995,: pp 156-167.
20. Musib, L.; Eppler, S.; Choo, E.; Deng, A.; Miles, D.; Hsu, B.; Rosen, L.; Sikic, B.; LoRusso, P.; Ma, W.; Goldman, J.; Fisher, G.; Weise, A.; Dy, G.; Chan, I.; Ware, J. Clinical pharmacokinetics of GDC-0973, an oral MEK inhibitor, in cancer patients: data from a phase 1 study Cancer Res. 2011, 71, 1304